According to the 2016 WHO classification revision, patients with DH translocations should be excluded from the DLBCL NOS category and placed within the novel category “High-grade B-cell lymphomas, with MYC and BCL2 or BCL6 translocations”. This evidence concerns the gene MYC and B-cell non-Hodgkin lymphoma.